Related Experiment Videos

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or

Maria Rosario¹, Jonathan L French², Nathanael L Dirks²

¹Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.

Journal of Crohn'S & Colitis

|February 1, 2018

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Maintenance of Efficacy Outcomes at Week 52 among Etrasimod Induction Responders: An Analysis from the Phase 3 ELEVATE UC 52 Trial.

Digestive diseases (Basel, Switzerland)·2026

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.

Paediatric drugs·2026

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

A decade of clinical data with vedolizumab: the past, present, and future.

Therapeutic advances in gastroenterology·2026

Pre-Crohn's Disease Stool From Discordant Siblings Promotes the Development of Colitis in Germ-Free Mice.

Gastroenterology·2026

Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial.

BMJ open gastroenterology·2026

See all related articles